Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease

[1]  S. Joo,et al.  Interaction between sarcopenia and nonalcoholic fatty liver disease , 2022, Clinical and molecular hepatology.

[2]  Canqing Yu,et al.  Association between metabolically healthy obesity and non-alcoholic fatty liver disease , 2022, Hepatology International.

[3]  Juan Wu,et al.  Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease , 2022, Frontiers in Nutrition.

[4]  E. Bugianesi,et al.  The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review , 2021, Frontiers in Endocrinology.

[5]  Dong Seok Lee,et al.  Association of obesity, visceral adiposity, and sarcopenia with an increased risk of metabolic syndrome: A retrospective study , 2021, PloS one.

[6]  Y. Cho,et al.  KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease , 2021, Clinical and molecular hepatology.

[7]  X. Fang,et al.  The interaction on hypertension between family history and diabetes and other risk factors , 2021, Scientific Reports.

[8]  K. Choi,et al.  Sarcopenia and fatty liver disease , 2019, Hepatology International.

[9]  C. Mantzoros,et al.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.

[10]  X. Fang,et al.  The effect of body mass index and its interaction with family history on hypertension: a case–control study , 2019, Clinical Hypertension.

[11]  L. V. Van Gaal,et al.  Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity? , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[12]  Paige L Williams,et al.  Estimating the Relative Excess Risk Due to Interaction in Clustered-Data Settings , 2018, American journal of epidemiology.

[13]  C. Lee,et al.  Effect of synergistic interaction between abnormal adiposity-related metabolism and prediabetes on microalbuminuria in the general population , 2017, PloS one.

[14]  Jana Pelclová,et al.  Associations of visceral fat area and physical activity levels with the risk of metabolic syndrome in postmenopausal women , 2017, Biogerontology.

[15]  Chao Lu,et al.  Retrospective study , 2016, Medicine.

[16]  Z. Wang,et al.  Obesity is an independent risk factor for non‐alcoholic fatty liver disease: evidence from a meta‐analysis of 21 cohort studies , 2016, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[17]  E. Kang,et al.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) , 2016, Hepatology.

[18]  Jin Hwa Kang,et al.  Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  Cheng-Li Lin,et al.  A population-based cohort study. , 2015 .

[20]  D. S̆timac,et al.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. , 2014, World journal of gastroenterology.

[21]  Soo Lim,et al.  Assessment of appendicular skeletal muscle mass by bioimpedance in older community-dwelling Korean adults. , 2014, Archives of gerontology and geriatrics.

[22]  H. J. Yoo,et al.  Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study , 2014, Hepatology.

[23]  L. Peng,et al.  Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. , 2014, Journal of the American Medical Directors Association.

[24]  Young Seol Kim,et al.  Sarcopenia Is Independently Associated with Cardiovascular Disease in Older Korean Adults: The Korea National Health and Nutrition Examination Survey (KNHANES) from 2009 , 2013, PloS one.

[25]  P. Marik,et al.  Narrative Review , 2012, Journal of intensive care medicine.

[26]  Yong-jun Choi,et al.  Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  Cuiying Wang,et al.  Sarcopenia in the elderly: Basic and clinical issues , 2012, Geriatrics & gerontology international.

[28]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[29]  G. Paolisso,et al.  Discovering pathways of sarcopenia in older adults: A role for insulin resistance on mitochondria dysfunction , 2011, The journal of nutrition, health & aging.

[30]  I. Rosenberg.  Sarcopenia: origins and clinical relevance. , 2011, Clinics in geriatric medicine.

[31]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[32]  T. Tsujinaka,et al.  InBody 720 as a new method of evaluating visceral obesity. , 2011, Hepato-gastroenterology.

[33]  H. J. Yoo,et al.  Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS) (Diabetes Care (2010) 33, (1497-1499)) , 2010 .

[34]  H. J. Yoo,et al.  Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes , 2010, Diabetes Care.

[35]  J. Yeon,et al.  Short Segment Hiatal Hernia: Is It a Clinically Significant Entity? , 2005, Journal of neurogastroenterology and motility.

[36]  H. J. Yoo,et al.  Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean Sarcopenic Obesity Study (KSOS) , 2009 .

[37]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  J. Kench,et al.  Visceral fat: A key mediator of steatohepatitis in metabolic liver disease , 2008, Hepatology.

[39]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[40]  G. Marchesini,et al.  Metabolic syndrome and NASH. , 2007, Clinics in liver disease.

[41]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[42]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[43]  Tomas Andersson,et al.  Calculating measures of biological interaction , 2005, European Journal of Epidemiology.

[44]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[45]  Robert Ross,et al.  Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability , 2002, Journal of the American Geriatrics Society.

[46]  R. Ross,et al.  Estimation of skeletal muscle mass by bioelectrical impedance analysis. , 2000, Journal of applied physiology.

[47]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[48]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.